Evotec (EVO) Competitors

Evotec (NASDAQ:EVO) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Does the media refer more to EVO or PTCT?

In the previous week, PTC Therapeutics had 8 more articles in the media than Evotec. MarketBeat recorded 10 mentions for PTC Therapeutics and 2 mentions for Evotec. PTC Therapeutics' average media sentiment score of 1.00 beat Evotec's score of 0.93 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, EVO or PTCT?

Evotec has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Which has higher valuation & earnings, EVO or PTCT?

Evotec has higher earnings, but lower revenue than PTC Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$777.05M	1.51	-$90.82M	N/A	N/A
PTC Therapeutics	$806.78M	5.38	-$626.60M	-$4.73	-11.63

Do insiders and institutionals hold more shares of EVO or PTCT?

5.8% of Evotec shares are owned by institutional investors. 1.0% of Evotec shares are owned by insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community prefer EVO or PTCT?

PTC Therapeutics received 562 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 61.87% of users gave PTC Therapeutics an outperform vote while only 54.55% of users gave Evotec an outperform vote.

Company	Underperform	Outperform
Evotec	Outperform Votes 6 54.55%	Underperform Votes 5 45.45%
PTC Therapeutics	Outperform Votes 568 61.87%	Underperform Votes 350 38.13%

Do analysts rate EVO or PTCT?

Evotec presently has a consensus price target of $5.93, suggesting a potential upside of 78.71%. PTC Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 16.38%. Given Evotec's higher probable upside, analysts clearly believe Evotec is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PTC Therapeutics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.53

Is EVO or PTCT more profitable?

Evotec has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	N/A	N/A	N/A
PTC Therapeutics	-50.32%	N/A	-16.44%

Summary

PTC Therapeutics beats Evotec on 10 of the 16 factors compared between the two stocks.